Search
Close this search box.

Singapore Backs AI-based Clinical Trial Tool Development with S$50,000 Investment

AI
Image used for information purpose only. Picture Credit: https://www.biospectrumasia.com

A team of healthcare professionals has been awarded $50,000 to advance their concept for an Artificial Intelligence (AI)-enabled tool designed to match cancer patients with relevant clinical trials. This recognition was bestowed upon them as part of the Duke-NUS Health Innovator Programme’s annual innovation challenge. The program, spanning nine months, is a pioneering fellowship in Singapore that brings together a diverse team of experts to address healthcare challenges under the mentorship of industry leaders.

Known as Team OncoPATH, their project seeks to enhance accessibility to clinical trials and streamline referrals for local and regional cancer patients. The platform, named OncoPATH, utilizes a Large Language Model to match patients with suitable trials based on information provided in a brief questionnaire, including diagnosis, cancer stage, mutational profile, and disease sites. Interested patients can then register for the matched trial(s), with formal consultations arranged at the relevant healthcare institution.

This year’s iteration of the Duke-NUS Health Innovator Programme focused on clinical needs in the fields of oncology and primary health, with five competing teams presenting their projects. These included an enhanced colorectal cancer screening kit, a self-test colposcopy device for cervical cancer screening, an improved blood glucose monitoring app for individuals with diabetes, and an AI health companion offering personalized cancer screening advice.

Moving forward, all participating teams will seek additional funding to further develop their innovations, guided by clinical and industry mentors.

Read More: Click Here

Share:

Facebook
Twitter
WhatsApp
LinkedIn

Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.